PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer representa

First Page		Document Content
Date: 2015-03-12 23:53:04 Pharmaceutical Benefits Scheme Pharmacology Myelofibrosis International Prognostic Scoring System IPSS Clinical trial Medicine Health Ruxolitinib		PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer representa Add to Reading List Source URL: pbs.gov.au Download Document from Source Website File Size: 31,74 KB Share Document on Facebook

	GLAL_A_375719 ++ DocID: 19fUF - View Document
	PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer DocID: 103lx - View Document
	PBAC STAKEHOLDER MEETING OUTCOME STATEMENT RUXOLITINIB FOR MYELOFIBROSIS 22 September 2014 The Sheraton Hotel, Melbourne Attendees Members of the Pharmaceutical Benefits Advisory Committee (PBAC), the consumer representa DocID: ZuUz - View Document
	Microsoft PowerPoint - LLS1104 - MDS slides - on background v14 (for pdf) [Compatibility Mode] DocID: YwaP - View Document
	Table 16.1 The World Health Organization[removed]classification of myelodysplasia. Subtype Peripheral blood DocID: XbLN - View Document